6-hydroxydopa has been researched along with tanshinone ii a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laev, SS; Lavrik, OI; Salakhutdinov, NF | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
1 review(s) available for 6-hydroxydopa and tanshinone ii a
| Article | Year |
|---|---|
Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Enzyme Inhibitors; Humans; Neoplasms; Oxidation-Reduction | 2017 |
1 other study(ies) available for 6-hydroxydopa and tanshinone ii a
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |